However, many large-scale and functional genomic analyses commonly demonstrate that the tumor suppressive features of PAX5 are inhibited by promoter hypermethylation events in non-hematological cancers [73,76,100,105,107,108]. Here, PAX5 is linked to hematopoietic and lymphoid cell neoplasm.